LONDON, ONTARIO--(Marketwire - Jan. 8, 2009) - Stellar Pharmaceuticals Inc. (“Stellar”) (OTCBB:SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported signing a licensing agreement for the distribution and sale of Uracyst® in Netherlands, Belgium and Luxemburg, with EuroCept B. V. (“EuroCept”), a specialty pharmaceutical sales and marketing company, based in Ankeveen, the Netherlands. EuroCept promotes prescription medicines for urology, anesthesia and psychiatry in the Netherlands, Belgium and Luxembourg. One of EuroCept’s major focus areas is urology, and Uracyst®, Stellar’s proprietary product, used in the treatment of interstitial cystitis and painful bladder syndrome, is treated mainly by urologists.
